Literature DB >> 21443554

Liver disease in the patient with Fontan circulation.

Fred M Wu1, Chinweike Ukomadu, Robert D Odze, Anne Marie Valente, John E Mayer, Michael G Earing.   

Abstract

The Fontan procedure has undergone many modifications since first being performed on a patient with tricuspid valve atresia in 1968. It is now the procedure of choice for individuals born with single-ventricle physiology or for those in whom a biventricular repair is not feasible. Forty years of experience with the Fontan procedure have gradually revealed the shortfalls of such a circulatory arrangement. Sequelae related to the underlying congenital anomaly or to the altered physiology of passive, nonpulsatile flow through the pulmonary arterial bed can result in failure of the Fontan circulation over time. Liver abnormalities including abnormalities in the clotting cascade have been well documented in Fontan patients. The clinical significance of these findings, however, has remained poorly understood. As Fontan survivors have increased in age and number, we have begun to better recognize subclinical hepatic dysfunction and the contribution of liver disease to adverse outcomes in this population. The purpose of this review is to summarize the existing data pertaining to liver disease in the Fontan population and to identify some questions that have yet to be answered.
© 2011 Copyright the Authors. Congenital Heart Disease © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21443554     DOI: 10.1111/j.1747-0803.2011.00504.x

Source DB:  PubMed          Journal:  Congenit Heart Dis        ISSN: 1747-079X            Impact factor:   2.007


  25 in total

1.  An Emphasis on Screening to Detect Liver Cirrhosis and Hepatocellular Carcinoma in Patients Having Undergone the Fontan Procedure in Early Childhood.

Authors:  Samragnyi Madala; Kira MacDougall; Abhishek Polavarapu; Dinesh Gurala; Vivek Gumaste; Gerard Morvillo
Journal:  Case Rep Gastroenterol       Date:  2020-11-23

2.  Serial evaluation of hepatic function profile after Fontan operation.

Authors:  R Kaulitz; P Haber; E Sturm; J Schäfer; M Hofbeck
Journal:  Herz       Date:  2013-05-08       Impact factor: 1.443

Review 3.  MR assessment of abdominal circulation in Fontan physiology.

Authors:  Shi-Joon Yoo; Milan Prsa; Daryl Schantz; Lars Grosse-Wortmann; Mike Seed; Tae Kyoung Kim; Rachel Wald; Rajiv Chaturvedi
Journal:  Int J Cardiovasc Imaging       Date:  2014-04-22       Impact factor: 2.357

Review 4.  Congenital heart disease-associated liver disease: a narrative review.

Authors:  Florian P Reiter; Nino J Hadjamu; Nicole Nagdyman; Reinhart Zachoval; Julia Mayerle; Enrico N De Toni; Harald Kaemmerer; Gerald Denk
Journal:  Cardiovasc Diagn Ther       Date:  2021-04

5.  Risk factors for major adverse events late after Fontan palliation.

Authors:  Robert W Elder; Nancy M McCabe; Emir Veledar; Brian E Kogon; Maan Jokhadar; Fred H Rodriguez; Michael E McConnell; Wendy M Book
Journal:  Congenit Heart Dis       Date:  2014-08-17       Impact factor: 2.007

6.  Magnetic Resonance Elastography: A Novel Technique for the Detection of Hepatic Fibrosis and Hepatocellular Carcinoma After the Fontan Operation.

Authors:  Joseph T Poterucha; Jonathan N Johnson; M Yasir Qureshi; Patrick W O'Leary; Patrick S Kamath; Ryan J Lennon; Crystal R Bonnichsen; Phillip M Young; Sudhakar K Venkatesh; Richard L Ehman; Sounak Gupta; Thomas C Smyrk; Joseph A Dearani; Carole A Warnes; Frank Cetta
Journal:  Mayo Clin Proc       Date:  2015-06-06       Impact factor: 7.616

7.  Transvenous hepatic biopsy in stable Fontan patients undergoing cardiac catheterization.

Authors:  William N Evans; Brody J Winn; Noel S Yumiaco; Alvaro Galindo; Abraham Rothman; Ruben J Acherman; Humberto Restrepo
Journal:  Pediatr Cardiol       Date:  2014-05-10       Impact factor: 1.655

8.  Congenital Heart Defects in Adults : A Field Guide for Cardiologists.

Authors:  Anitra Romfh; Francesca Romana Pluchinotta; Prashob Porayette; Anne Marie Valente; Stephen P Sanders
Journal:  J Clin Exp Cardiolog       Date:  2012-06-15

9.  Liver cirrhosis in Fontan patients does not affect 1-year post-heart transplant mortality or markers of liver function.

Authors:  Kathleen E Simpson; Amir Esmaeeli; Geetika Khanna; Francis White; Yumirle Turnmelle; Pirooz Eghtesady; Umar Boston; Charles E Canter
Journal:  J Heart Lung Transplant       Date:  2013-10-25       Impact factor: 10.247

10.  Fontan Liver Disease: Review of an Emerging Epidemic and Management Options.

Authors:  Elisa Bradley; Benjamin Hendrickson; Curt Daniels
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.